Post-marketing surveillance of drugs.
作者信息
Harcus A W, Ward A E, Smith D W
出版信息
Br Med J. 1979 Oct 6;2(6194):867. doi: 10.1136/bmj.2.6194.867-c.
Abstract
摘要
相似文献
1
Post-marketing surveillance of drugs.药品上市后监测
Br Med J. 1979 Oct 6;2(6194):867. doi: 10.1136/bmj.2.6194.867-c.
2
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
3
Withdrawal syndrome.
Nat Med. 2004 Nov;10(11):1143. doi: 10.1038/nm1104-1143.
4
Methodology of monitored release of a new preparation: buprenorphine.一种新制剂：丁丙诺啡的控释方法学。
Br Med J. 1979 Jul 21;2(6183):163-5. doi: 10.1136/bmj.2.6183.163.
5
Post-marketing drug surveillance: a comparison of methods.药品上市后监测：方法比较
Am J Pharm Sci Support Public Health. 1978 May-Jun;150(3):72-80.
6
[Structured introduction of new drug therapies: valuable initiative--transparency required].[新药疗法的结构化介绍：宝贵的举措——需要透明度]
Lakartidningen. 2009;106(1-2):51.
7
Post-marketing surveillance of new medicines.新药上市后监测
Br Med J. 1977 Nov 5;2(6096):1218. doi: 10.1136/bmj.2.6096.1218-a.
8
[Opportunity and challenge of post-marketing evaluation of traditional Chinese medicine].[中药上市后评价的机遇与挑战]
Zhongguo Zhong Yao Za Zhi. 2014 Sep;39(18):3427-9.
9
Post marketing surveillance of sublingual buprenorphine naloxone combination tablets.舌下含服丁丙诺啡纳洛酮复方片剂的上市后监测
Indian J Physiol Pharmacol. 2012 Oct-Dec;56(4):359-66.
10
[A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].[一种新药结构化引入的模型。目的是为所有患者提供适当的治疗]
Lakartidningen. 2008;105(42):2917-22.
本文引用的文献
1
Detection of drug-induced disease.药物性疾病的检测
Br J Clin Pharmacol. 1979 Jan;7(1):13-8. doi: 10.1111/j.1365-2125.1979.tb00890.x.
Zotero 插件